Fatma Diyana Mohd Bukhari

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Natural <i>Plasmodium inui</i> Infections in Humans and <i>Anopheles cracens</i> Mosquito, Malaysia

Jonathan Wee Kent Liew, Fatma Diyana Mohd Bukhari, Nantha Kumar Jeyaprakasam et al. · Emerging infectious diseases · 2021 · 43 citations · Full text

Veterinary Medicine, Biology, Infectious Diseases +17

Prevalence of Asymptomatic and/or Low-Density Malaria Infection among High-Risk Groups in Peninsular Malaysia

Naqib Rafieqin Noordin, Phone Youth Lee, Fatma Diyana Mohd Bukhari et al. · American Journal of Tropical Medicine and Hygiene · 2020 · 34 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Colorimetric detection of SARS-CoV-2 by uracil-DNA glycosylase (UDG) reverse transcription loop-mediated isothermal amplification (RT-LAMP)

Meng Yee Lai, Fatma Diyana Mohd Bukhari, Nur Zulaikha Zulkefli et al. · International Journal of Infectious Diseases · 2022 · 19 citations · Full text

Life Sciences, Microbiology, Molecular Biology +12